February 2026

The most significant Form 483 issued in February came from the FDA’s inspection of Aurobindo Pharma’s Unit-VII at the Special Economic Zone in Jedcherla, Telangana. The inspection, conducted from January 28 to February 10, 2026, resulted in 9 observations across the oral solid dosage manufacturing facility.

Aurobindo’s initial disclosure characterised all observations as “procedural in nature” with no critical or data-integrity issues. Subsequent reporting told a different story. One observation cited a microbiologist who falsified sample collection data — a finding that goes beyond procedural deficiency into deliberate data integrity fraud. Inspectors also documented E. coli and bird droppings within the facility, alongside findings related to inadequate cleaning of equipment and utensils.

This pattern — a company characterising findings as routine while the actual 483 reveals systemic issues — is one quality leaders should watch carefully. Aurobindo’s shares fell 4% on the news.

Separately, Aurobindo’s Unit-III at Pashamylaram received 11 observations during a concurrent inspection, further concentrating FDA scrutiny on the company’s Indian manufacturing network. Between 2022 and 2024, the agency conducted 114 unannounced inspections in India, 94 of which resulted in 483 observations.

Beyond the four primary warning letters, the FDA also issued four warning letters to companies distributing at-home blood specimen collection kits without pre-market authorisation, and more than 40 warning letters and 100 cease-and-desist letters to compounding pharmacies for deceptive advertising related to GLP-1 medications.

February was an active month for FDA approvals — 3 novel drugs, 3 expanded indications, and 4 biosimilars. For quality leaders, every approval is a manufacturing event: new products mean new process validations, new analytical methods, and new supply chains to qualify.

Biosimilar activity accelerated. The FDA approved four denosumab biosimilars in February — Boncresa and Oziltus (Amneal/mAbxience) and Osvyrti and Jubereq (Fresenius Kabi) — all referencing Amgen’s Prolia and Xgeva. Two pairs of biosimilars approved in a single month for the same reference product signals intense competitive pressure on the biologics manufacturing side.

Meanwhile, the EMA’s CHMP recommended 6 biosimilars for EU approval in its February meeting: insulin lispro, insulin aspart, etanercept, pertuzumab, tocilizumab, and teriparatide — spanning the full biologics spectrum from small peptides to monoclonal antibodies. Combined with the FDA approvals, February saw 10 biosimilar regulatory milestones across the two largest markets.

Pipeline signals for manufacturing planning. Breakthrough therapy designations were granted for luvesilocin (Reunion Neuroscience, postpartum depression), NGN-401 (Neurogene, Rett syndrome gene therapy), and trastuzumab deruxtecan (AstraZeneca/Daiichi Sankyo, early breast cancer). BMS’s iberdomide received priority review for multiple myeloma with a PDUFA date of August 17, 2026. Each of these represents manufacturing scale-up pressure within the next 12-18 months.

The reshoring signal is now backed by capital. J&J’s $1 billion cell therapy investment in Pennsylvania is the largest single-facility pharma manufacturing commitment announced in February. The facility will focus on next-generation cell therapies — a manufacturing category that requires entirely different GMP paradigms than traditional small-molecule or even conventional biologics production. The 500 biomanufacturing roles signal the scale of the workforce challenge: cell therapy manufacturing specialists are already in short supply.

AbbVie’s $380 million API expansion is notable for two reasons. First, it explicitly integrates AI and advanced manufacturing technologies into the facility design — one of the first large-scale API investments to do so publicly. Second, it targets neuroscience and obesity medications, aligning manufacturing capacity with the two fastest-growing therapeutic categories.

The Bora-GSK $250 million CDMO renewal underscores a parallel trend: major pharma companies are locking in CDMO capacity through longer-term, higher-value agreements rather than project-by-project outsourcing. This is a direct response to the supply chain disruptions of 2020-2024.

India’s Biopharma SHAKTI programme (Union Budget 2026-27) allocated 10,000 crore INR (~$1.15 billion) over five years to build a comprehensive biopharma ecosystem, alongside PLI scheme incentives for domestic GLP-1 production ahead of semaglutide patent expiration. India is investing in capacity at the same time the FDA is incentivising US-based production — creating a bifurcated manufacturing landscape that quality leaders must navigate.

The PIC/S Annex 15 revision deserves immediate attention. The proposed changes extend qualification and validation requirements to active substance manufacturers — a scope expansion that will affect API production globally. Quality leaders at companies with both finished dosage and API manufacturing should start impact assessments now, before the consultation period closes on April 9.

The PreCheck pilot, combined with the GLP-1 enforcement actions and ongoing foreign manufacturing scrutiny, makes the regulatory direction clear: the FDA is creating structural incentives for domestic production while increasing the cost of offshore non-compliance.

The Asteria Health recall is notable for scale — nearly 720,000 subcutaneous hormone pellets — and for the FDA’s Class II escalation, indicating potential for temporary or medically reversible adverse health consequences.

The OPDP enforcement acceleration represents a broader shift: the agency is monitoring both direct-to-consumer and healthcare professional-directed promotional content with renewed intensity. Separately, the FDA issued a statement on improving adverse event reporting for compounded drugs, signalling tighter post-market surveillance for the compounding sector.

February revealed the tension at the centre of pharma’s current moment: billions flowing into new capacity on one side, thousands of jobs being cut on the other. The restructuring is not random — it reflects a deliberate reallocation of resources toward cell therapy, AI-enabled manufacturing, and obesity/neuroscience therapeutics, and away from mature portfolios.

Workforce contraction is concentrated, not uniform. Viatris announced the largest restructuring — ~3,200 positions (10% of its global workforce) over three years, with $700-850 million in restructuring charges. Merck is cutting 154 roles at Durham, NC as it winds down Gardasil production due to reduced demand, and 204 at Rahway HQ as part of a broader 6,000-job reduction targeting $3 billion in savings by 2027. BMS filed a WARN notice for 110 positions in Lawrence Township, NJ. GSK is reorganising up to 350 R&D roles in the US and UK.

The quality implication is direct: restructuring creates institutional knowledge loss. When experienced manufacturing and quality professionals leave — particularly from sites with complex regulatory histories — the risk of compliance gaps increases. Quality leaders at companies undergoing restructuring should prioritise knowledge transfer protocols, ensure critical quality roles are not hollowed out, and monitor whether reduced headcount is creating pressure to cut procedural corners.

The compounding sector is under coordinated regulatory pressure. February’s enforcement actions — warning letters, GLP-1 API restrictions, import alerts, the Asteria Health recall, and the OPDP advertising crackdown — represent a coordinated FDA strategy to tighten oversight, particularly around sterility assurance, potency testing, and marketing claims. Regulatory expectations established in compounding enforcement often migrate to broader CGMP standards.

The manufacturing landscape is bifurcating. On one axis: the US and EU are incentivising domestic production through programmes like PreCheck and India’s Biopharma SHAKTI. On another: $14 billion in M&A is reshaping which companies own which manufacturing capabilities. On a third: cell therapy, oral biologics, and AI-enabled production are creating entirely new GMP categories that existing validation frameworks weren’t designed for. Quality leaders need manufacturing network strategies that account for all three axes simultaneously.

The approval-to-manufacturing pipeline is accelerating. Ten biosimilar regulatory milestones across FDA and EMA in a single month. Breakthrough therapy designations for gene therapies, psychedelics, and ADCs. Four denosumab biosimilars approved simultaneously. The speed and diversity of new products entering the market is creating validation and manufacturing capacity pressure that most organisations are not staffed to absorb.

AI regulation is crystallising faster than expected. CDER’s 2026 guidance agenda explicitly includes AI in manufacturing. The FDA-EMA joint principles provide 10 guiding principles. PIC/S Annex 15 is being revised to extend to API manufacturers. The regulatory framework is taking shape from multiple directions simultaneously — and the window to begin documenting validation approaches is now.

Workforce restructuring creates hidden quality risk. When Viatris cuts 3,200 positions and Merck eliminates 6,000 roles over two years, the immediate financial narrative obscures the quality narrative. Institutional knowledge about process deviations, equipment quirks, and regulatory history walks out the door. The FDA’s ongoing finding of data integrity failures at Indian manufacturing sites — 94 out of 114 unannounced inspections resulting in 483s — may partly reflect this dynamic: experienced QA personnel being stretched too thin or replaced too quickly.

Treat data integrity as a behavioural risk, not just a systems problem. The Aurobindo falsification finding is a warning. Audit trail software and electronic signatures are necessary but not sufficient — you also need monitoring for anomalous patterns, rotation of critical quality roles, and a culture where reporting concerns is safer than concealing them.

Start PIC/S Annex 15 impact assessments now. The proposed extension of qualification and validation requirements to API manufacturers will affect a significant portion of the industry. The consultation closes April 9. Quality leaders should review the draft, assess impact on their API manufacturing operations, and submit comments.

Map your manufacturing network against the reshoring trend. The PreCheck pilot, AbbVie’s AI-integrated API plant, J&J’s cell therapy facility, and India’s SHAKTI programme all point the same direction: manufacturing location is becoming a regulatory variable, not just a cost variable. Evaluate where your current and planned capacity sits relative to these signals.

Prepare for AI-related regulatory expectations. Companies already using or evaluating AI for process optimisation, deviation detection, or batch review should begin documenting their validation approach against the FDA-EMA joint principles and CDER’s forthcoming guidance.

Budget for biosimilar manufacturing complexity. Four denosumab biosimilars approved in one month means the competitive pressure on biologics manufacturing cost and quality is intensifying. If you manufacture reference biologics or biosimilars, your cost of quality is about to be scrutinised more intensely by commercial teams.

Protect institutional knowledge during restructuring. If your organisation is undergoing workforce reductions, ensure that knowledge transfer from departing quality and manufacturing personnel is formalised — not left to chance. The correlation between workforce disruption and compliance findings is not coincidental.

Track these signals continuously. Monthly reports provide a snapshot — but enforcement patterns shift weekly. Tools like FDA Tracker provide real-time visibility into 483 observations, warning letters, and inspection trends as they are published.